After a 54% rise year-to-date, at the current levels, Catalent stock (NYSE: CTLT), a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, has little room for growth, in our view.
After a 54% rise year-to-date, at the current levels, Catalent stock (NYSE: CTLT), a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, has little room for growth, in our view.
Share this Article
Recommended